Affordable and Safe Prescription Drug Importation Act of 2025
Key claim: The Affordable and Safe Prescription Drug Importation Act of 2025 would require HHS to allow importation of qualifying prescription drugs including biologics from Canada, the UK, Switzerland, and EU member states without a prior safety certification, and would let individuals fill U.S. prescriptions at licensed foreign pharmacies for personal use.
Abstract
(HR3162 · 119th Congress) Affordable and Safe Prescription Drug Importation Act of 2025 This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported. Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs. The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements. The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin. Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS. Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription. Latest action (2025-05-01): Referred to the House Committee on Energy and Commerce.
Why this matters
Drug importation has long been statutorily authorized but blocked in practice by the HHS certification requirement; removing that gate and adding UK/Switzerland/EU sources would materially change how U.S. patients and pharmacies could source biologics like insulin. The personal-use foreign-pharmacy provision would also formalize a pathway that today sits in enforcement-discretion gray area, with direct implications for what patients pay out of pocket.